Éverton de Almeida Alves Barbosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Éverton de Almeida Alves Barbosa has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Abelardo Silva Júnior
Departamento de Veterinária, Universidade Federal de Viçosa, Viçosa, MG, Brazil
5 shared publications- Gustavo Costa Bressan
Departamento de Bioquímica e Biologia Molecular, Universidade Federal de Viçosa, Av. P. H. Rolfs, s/n, Campus Universitário, CEP: 36570-000 Viçosa, MG, Brasil
5 shared publications Juliana Lopes Rangel Fietto
5 shared publicationsMárcia Rogéria Almeida
Departamento de Bioquímica e Biologia Molecular, Universidade Federal de Viçosa, Viçosa, MG, Brazil
5 shared publicationsMarcus Vinícius de Andrade Barros
4 shared publications- Raoni Pais Siqueira
Universidade Federal de Viçosa, Departamento de Bioquímica e Biologia Molecular, Viçosa, MG, Brazil
4 shared publications
Latest Publications
- Open Access
- 18 March 2026
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1365
Antimetastatic activity evaluation of diamides inspired by SRPK inhibitor N-[2-(piperidin-1-yl)-5-(trifluoromethyl) phenyl] isonicotinamide (SRPIN340)
- 18 March 2026
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1365
Open AccessAntimetastatic activity evaluation of diamides inspired by SRPK inhibitor N-[2-(piperidin-1-yl)-5-(trifluoromethyl) phenyl] isonicotinamide (SRPIN340)
- 1 September 2019
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 137, 205-214
Insights into the full-length SRPK2 structure and its hydrodynamic behavior
- 1 September 2019
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 137, 205-214
Insights into the full-length SRPK2 structure and its hydrodynamic behavior
- 1 October 2018
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 356, 214-223
Antimetastatic effect of the pharmacological inhibition of serine/arginine-rich protein kinases (SRPK) in murine melanoma
- 1 October 2018
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 356, 214-223
Antimetastatic effect of the pharmacological inhibition of serine/arginine-rich protein kinases (SRPK) in murine melanoma
- 1 October 2017
- Published by Elsevier in Food Research International
- Vol. 100, 674-681
Formation and characterization of supramolecular structures of β-lactoglobulin and lactoferrin proteins
- 1 October 2017
- Published by Elsevier in Food Research International
- Vol. 100, 674-681
Formation and characterization of supramolecular structures of β-lactoglobulin and lactoferrin proteins
- Open Access
- 5 August 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (8) , e0134882
Potential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340)
Dysregulation of pre-mRNA splicing machinery activity has been related to the biogenesis of several diseases. The serine/arginine-rich protein kinase family (SRPKs) plays a critical role in regulating pre-mRNA splicing events through the extensive phosphorylation of splicing factors from the family of serine/arginine-rich proteins (SR proteins). Previous investigations have described the overexpression of SRPK1 and SRPK2 in leukemia and other cancer types, suggesting that they would be useful targets for developing novel antitumor strategies. Herein, we evaluated the effect of selective pharmacological SRPK inhibition by N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)isonicotinamide (SRPIN340) on the viability of lymphoid and myeloid leukemia cell lines. Along with significant cytotoxic activity, the effect of treatments in regulating the phosphorylation of the SR protein family and in altering the expression of MAP2K1, MAP2K2, VEGF and FAS genes were also assessed. Furthermore, we found that pharmacological inhibition of SRPKs can trigger early and late events of apoptosis. Finally, intrinsic tryptophan fluorescence emission, molecular docking and molecular dynamics were analyzed to gain structural information on the SRPK/SRPIN340 complex. These data suggest that SRPK pharmacological inhibition should be considered as an alternative therapeutic strategy for fighting leukemias. Moreover, the obtained SRPK-ligand interaction data provide useful structural information to guide further medicinal chemistry efforts towards the development of novel drug candidates.
- 5 August 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (8) , e0134882
Open AccessPotential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340)
Dysregulation of pre-mRNA splicing machinery activity has been related to the biogenesis of several diseases. The serine/arginine-rich protein kinase family (SRPKs) plays a critical role in regulating pre-mRNA splicing events through the extensive phosphorylation of splicing factors from the family of serine/arginine-rich proteins (SR proteins). Previous investigations have described the overexpression of SRPK1 and SRPK2 in leukemia and other cancer types, suggesting that they would be useful targets for developing novel antitumor strategies. Herein, we evaluated the effect of selective pharmacological SRPK inhibition by N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)isonicotinamide (SRPIN340) on the viability of lymphoid and myeloid leukemia cell lines. Along with significant cytotoxic activity, the effect of treatments in regulating the phosphorylation of the SR protein family and in altering the expression of MAP2K1, MAP2K2, VEGF and FAS genes were also assessed. Furthermore, we found that pharmacological inhibition of SRPKs can trigger early and late events of apoptosis. Finally, intrinsic tryptophan fluorescence emission, molecular docking and molecular dynamics were analyzed to gain structural information on the SRPK/SRPIN340 complex. These data suggest that SRPK pharmacological inhibition should be considered as an alternative therapeutic strategy for fighting leukemias. Moreover, the obtained SRPK-ligand interaction data provide useful structural information to guide further medicinal chemistry efforts towards the development of novel drug candidates.
- Open Access
- 1 January 2015
- Published by Wiley in BioMed Research International
- Vol. 2015, 1-12
Splicing Regulators and Their Roles in Cancer Biology and Therapy
Alternative splicing allows cells to expand the encoding potential of their genomes. In this elegant mechanism, a single gene can yield protein isoforms with even antagonistic functions depending on the cellular physiological context. Alterations in splicing regulatory factors activity in cancer cells, however, can generate an abnormal protein expression pattern that promotes growth, survival, and other processes, which are relevant to tumor biology. In this review, we discuss dysregulated alternative splicing events and regulatory factors that impact pathways related to cancer. The SR proteins and their regulatory kinases SRPKs and CLKs have been frequently found altered in tumors and are examined in more detail. Finally, perspectives that support splicing machinery as target for the development of novel anticancer therapies are discussed.
- 1 January 2015
- Published by Wiley in BioMed Research International
- Vol. 2015, 1-12
Open AccessSplicing Regulators and Their Roles in Cancer Biology and Therapy
Alternative splicing allows cells to expand the encoding potential of their genomes. In this elegant mechanism, a single gene can yield protein isoforms with even antagonistic functions depending on the cellular physiological context. Alterations in splicing regulatory factors activity in cancer cells, however, can generate an abnormal protein expression pattern that promotes growth, survival, and other processes, which are relevant to tumor biology. In this review, we discuss dysregulated alternative splicing events and regulatory factors that impact pathways related to cancer. The SR proteins and their regulatory kinases SRPKs and CLKs have been frequently found altered in tumors and are examined in more detail. Finally, perspectives that support splicing machinery as target for the development of novel anticancer therapies are discussed.
- Open Access
- 22 November 2013
- Published by Sociedade Brasileira de Bioquimica e Biologia Molecular - SBBq in Revista de Ensino de Bioquímica
- Vol. 11 (1) , 1-10
Programa de Tutoria em Bioquímica na Universidade Federal de Viçosa
Este estudo descreve o Programa de Tutoria em Bioquímica (TutBQI) da Universidade Federal de Viçosa, uma atividade extracurricular proposta para complementar as aulas expositivas tradicionais na disciplina de Bioquímica Fundamental (BQI 100). Dez anos após a implantação do TutBQI, são relatados os impactos positivos do programa sobre o índice de reprovação e o rendimento médio dos estudantes da BQI100. São também apresentadas as limitações do programa.
- 22 November 2013
- Published by Sociedade Brasileira de Bioquimica e Biologia Molecular - SBBq in Revista de Ensino de Bioquímica
- Vol. 11 (1) , 1-10
Open AccessPrograma de Tutoria em Bioquímica na Universidade Federal de Viçosa
Este estudo descreve o Programa de Tutoria em Bioquímica (TutBQI) da Universidade Federal de Viçosa, uma atividade extracurricular proposta para complementar as aulas expositivas tradicionais na disciplina de Bioquímica Fundamental (BQI 100). Dez anos após a implantação do TutBQI, são relatados os impactos positivos do programa sobre o índice de reprovação e o rendimento médio dos estudantes da BQI100. São também apresentadas as limitações do programa.